AVE Stock Overview
A biotechnology company, engages in the development and commercialization of human and animal health related products using its proprietary drug delivery system and Tocopherol Phosphate Mixture in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Avecho Biotechnology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.002 |
| 52 Week High | AU$0.005 |
| 52 Week Low | AU$0.001 |
| Beta | 2.12 |
| 11 Month Change | 0% |
| 3 Month Change | -33.33% |
| 1 Year Change | -50.00% |
| 33 Year Change | -87.50% |
| 5 Year Change | -50.00% |
| Change since IPO | -99.58% |
Recent News & Updates
Recent updates
Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth
Jan 13
Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation
May 31Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely
Jul 14We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth
Mar 23We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate
Dec 08
Shareholder Returns
| AVE | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -33.3% | -11.8% | 1.5% |
| 1Y | -50.0% | 39.8% | 17.2% |
Return vs Industry: AVE underperformed the Australian Pharmaceuticals industry which returned 39.8% over the past year.
Return vs Market: AVE underperformed the Australian Market which returned 17.2% over the past year.
Price Volatility
| AVE volatility | |
|---|---|
| AVE Average Weekly Movement | 48.1% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: AVE's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: AVE's weekly volatility (48%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | n/a | Paul Gavin | avecho.com.au |
Avecho Biotechnology Limited, a biotechnology company, engages in the development and commercialization of human and animal health related products using its proprietary drug delivery system and Tocopherol Phosphate Mixture in Australia. The company operates through Production and Human Health segments. It also produces and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations.
Avecho Biotechnology Limited Fundamentals Summary
| AVE fundamental statistics | |
|---|---|
| Market cap | AU$6.34m |
| Earnings (TTM) | -AU$3.48m |
| Revenue (TTM) | AU$339.30k |
18.7x
P/S Ratio-1.8x
P/E RatioIs AVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVE income statement (TTM) | |
|---|---|
| Revenue | AU$339.30k |
| Cost of Revenue | AU$494.03k |
| Gross Profit | -AU$154.73k |
| Other Expenses | AU$3.33m |
| Earnings | -AU$3.48m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0011 |
| Gross Margin | -45.60% |
| Net Profit Margin | -1,026.91% |
| Debt/Equity Ratio | 0% |
How did AVE perform over the long term?
See historical performance and comparison